Abstract:The DNA damage response (DDR) encompasses the detection and repair of DNA lesions and is fundamental to the maintenance of genome integrity. Germline DDR alterations underlie hereditary chromosome instability syndromes by promoting the acquisition of pathogenic structural variants in hematopoietic cells, resulting in increased predisposition to hematologic malignancies. Also frequent in hematologic malignancies are somatic mutations of DDR genes, typically arising from replication stress triggered by oncogene activation or deregulated tumor proliferation that provides a selective pressure for DDR loss. These defects impair homology-directed DNA repair or replication stress response, leading to an excessive reliance on error-prone DNA repair mechanisms that results in genomic instability and tumor progression. In hematologic malignancies, loss-of-function DDR alterations confer clonal growth advantage and adverse prognostic impact, but may also provide therapeutic opportunities. Selective targeting of functional dependencies arising from these defects could achieve synthetic lethality, a therapeutic concept exemplified by inhibition of poly(ADP-ribose) polymerase or the ATR-CHK1-WEE1 axis in malignancies harboring the BRCAness phenotype or genetic defects that increase replication stress. Furthermore, the role of DDR defects as a source of tumor immunogenicity, as well as their impact on the crosstalk between DDR, inflammation and tumor immunity are increasingly recognized, thus providing rationale for combining DDR modulation with immune modulation. The nature of the DDR-immune interface and the cellular vulnerabilities conferred by DDR defects may nonetheless be disease-specific and remain incompletely understood in many hematologic malignancies. Their comprehensive elucidation will be critical for optimizing therapeutic strategies to target DDR defects in these diseases.-

When DNA-damage responses meet innate and adaptive immunity

The crosstalk between DNA-damage responses and innate immunity

DNA Damage Response and Immune Defense

DNA damage repair and cancer immunotherapy

DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining Immunotherapy

When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity

DNA Double-Strand Break Repair and Nucleic Acid-Related Immunity.

The Roles of DNA Damage Response Machineries in Maintaining Genome Stability&Cellular Homeo-stasis

DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies

Connecting the Dots: From DNA Damage and Repair to Aging

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy

Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies

Targeting DNA damage response pathways in cancer

Role of DNA Repair Defects in Predicting Immunotherapy Response

Regulators in the DNA Damage Response.

DNA Damage Checkpoint Recovery and Cancer Development

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

The Crosstalk Between DNA Repair and Immune Responses

Home and Away: The Role of Non-Coding RNA in Intracellular and Intercellular DNA Damage Response

Sensing Bacterial-Induced DNA Damaging Effects via Natural Killer Group 2 Member D Immune Receptor: From Dysbiosis to Autoimmunity and Carcinogenesis